JO
CADL icon

John Overdeck’s Candel Therapeutics CADL Stock Holding History

John Overdeck’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$337K Sell
32,731
-60,769
-65% -$459K ﹤0.01% 4452
2026
Q1 		$458K Sell
93,500
-5,700
-6% -$31K ﹤0.01% 3789
2025
Q4 		$560K Sell
99,200
-36,916
-27% -$199K ﹤0.01% 3242
2025
Q3 		$694K Sell
136,116
-233,079
-63% -$1.35M ﹤0.01% 2813
2025
Q2 		$1.87M Buy
+369,195
New +$1.9M ﹤0.01% 1882
2024
Q2 		– Sell
-13,409
Closed -$21.2K – 3052
2024
Q1 		$21.2K Buy
+13,409
New +$19.9K ﹤0.01% 2926

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

John Overdeck's CADL Position: Q2 2026 in Review

John Overdeck reduced its Candel Therapeutics (CADL) stake by 65% in Q2 2026, selling an estimated $459K and leaving 32,731 shares worth $337K. The position accounts for ﹤0.01% of the portfolio, ranked #4452.

John Overdeck first reported a position in CADL in Q1 2024 and has held it in 6 quarters since. The position peaked at $1.87M in Q2 2025. 137 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • John Overdeck held 32,731 shares of Candel Therapeutics worth $337K as of Q2 2026.
  • John Overdeck sold 60,769 Candel Therapeutics shares in Q2 2026, an estimated $459K.
  • Candel Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4452 holding.
  • John Overdeck first reported a position in Candel Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • John Overdeck's Candel Therapeutics position peaked at $1.87M in Q2 2025.
  • 137 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.